Pharmacokinetics of Busulfan: gastrointestinal absorption and the influence of DMSO

Authors

  • MA Navarro Moreno Dpto. de Ciencias Experimentales y Matemáticas, Facultad de Ciencias Experimentales, Universidad Católica de Valencia San Vicente Mártir, Valencia (Spain)
  • A Moreno Gálvez Dpto. de Ciencias Experimentales y Matemáticas, Facultad de Ciencias Experimentales, Universidad Católica de Valencia San Vicente Mártir, Valencia (Spain)
  • E Moreno Gálvez Dpto. de Ciencias Experimentales y Matemáticas, Facultad de Ciencias Experimentales, Universidad Católica de Valencia San Vicente Mártir, Valencia (Spain)

Keywords:

Pharmacokinetics, Busulfan, Oral, Rats, DMSO

Abstract

We have studied the pharmacokinetics of gastrointestinal absorption of busulfan in two groups of rats,after oral administration. The dose effect on the value of the absorption constant (Ka) and thenormalized maximum concentration (Cmax), presenting both parameters decreased with increasingdose from 0.5 to 5 mg. Using a model with monocompartimental apparent first order absorptionallows an adequate description of the profile of plasma levels of antineoplastic. The dimethylsulfoxideused as busulfan solvent, does not interfere with oral pharmacokinetic parameters of it.

Downloads

Download data is not yet available.

References

Hassan M, Öberg G, Ericson K, Ehrsson H, Eriksson L, Ingvar M et al. In vivo distribution of [11C]-busulfan in cynomolgus monkey and in the brain of a human patient. Cancer Chemother Pharmacology 1992; 30:81-85.

Nadkarni MV, Trams EG, Smith PK. Preliminary studies on the distribution and fate of TEM, TEPA and myleran in the human. Cancer Research 1959; 19:713-718.

Hassan M., Ehrsson H., Wallin Y. y Eksborg S. “Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain”. Eur. J. Drug Metab. Pharmacokinet., 13: 301-305, (1988).

Vassal G, Fischer A, Challine D, Boland Y, Ledheist F, Lemerle et al. Busulfan Disposition Below the Age of Three: Alteration in Children with Lysosomal Storage Disease. Blood 1993; 82:1030-1034.

Ehrsson H, Hassan M, Ehrnebo M, Beran M. Busulfan kinetics. Clin. Pharmacol. Ther 1983; 34, 86.

Schuler U, Schroer S, Kühnle A, Blanz J, Mewes K, Kumbier I et al.Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplantation 1994; 14:759-765.

Hassan M, Öberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur. J. Clin. Pharmacol 1989; 36:525-530.

Downloads

Published

2010-03-20

How to Cite

1.
Navarro Moreno M, Moreno Gálvez A, Moreno Gálvez E. Pharmacokinetics of Busulfan: gastrointestinal absorption and the influence of DMSO. Ars Pharm [Internet]. 2010 Mar. 20 [cited 2024 Jul. 22];51(1):37-48. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/4844

Issue

Vol. 51 No. 1 (2010)

Section

Original Articles

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).